JAZZ Q1 2020 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$535M+5.2% YoY

Gross Profit

$506M94.6% margin

Operating Income

-$190M-35.5% margin

Net Income

-$158M-29.5% margin

EPS (Diluted)

$-2.82

QoQ Revenue Growth

-8.1%

Cash Flow

Operating Cash Flow

$273M

Free Cash Flow

$53M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$5.2B

Total Liabilities

$2.4B

Stockholders' Equity

$2.8B

Cash & Equivalents

$702M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$535M	$508M	+5.2%
Gross Profit	$506M	$475M	+6.6%
Operating Income	-$190M	$134M	-241.8%
Net Income	-$158M	$85M	-285.2%

Revenue Segments

Product And Services, Product Sales

$530M50%

Xyrem

$408M38%

Defitelio/Defibrotide

$47M4%

Erwinaze And Erwinase

$38M4%

Vyxeos

$33M3%

Product And Services, Royalties And Contract Revenue

$5M0%

Other Products

$3M0%

Sunosi

$2M0%

Geographic Segments

UNITED STATES

$478M89%

Europe

$42M8%

Other Countries

$15M3%